Sun Pharmaceutical Industries reported a 28% year-on-year jump in net profit to Rs 3,040 crore for Q2 FY25, surpassing market expectations. The strong earnings were driven by favorable seasonality and robust sales in the specialty segment. Revenue from operations rose 9% to Rs 13,291 crore, closely aligning with analysts’ estimates.
The company’s EBITDA margin expanded to 29.6% from 26.1% a year ago, with the revenue balance successfully offsetting higher research and development expenses to expand its specialty portfolio. Sun Pharma’s focus on innovation and specialty drugs bolsters financial performance in an otherwise competitive market.
Do you have a news tip for Lakshmishree reporters? Please email us at media@lakshmishree.com
Source: Moneycontrol
News Desk
